Thyroid-associated ophthalmopathy (TAO) is an autoimmune disease. Recent studies have found the aberrant epigenetics in TAO, including DNA methylation, noncoding RNAs, and histone modification. Many genes have an aberrant level of methylation in TAO. For example, higher levels are found in CD14, MBP, ANGLE1, LYAR and lower levels in DRD4 and BOLL. Non-coding RNAs are involved in the immune response (miR-146a, miR-155, miR-96, miR-183), fibrosis regulation (miR-146a, miR-21, miR-29), adipogenesis (miR-27) and are thought to play roles in TAO. MicroRNA is also related to the clinical activity score (miRLet7d- 5p) and may be a predictor of glucocorticoid therapy (miR-224-5p). The quantities of H4 in TAO are increased compared with euthyroid control subjects, and the role of histone modifications in Graves' disease may lead to better understanding of its role in TAO. More studies are needed to explain the role of epigenetics in TAO and provide potential therapeutic strategies.
CITATION STYLE
Cao, J. M., Wang, N., Hou, S. Y., Qi, X., & Xiong, W. (2021, September 18). Epigenetics effect on pathogenesis of thyroid-associated ophthalmopathy. International Journal of Ophthalmology. International Journal of Ophthalmology (c/o Editorial Office). https://doi.org/10.18240/ijo.2021.09.22
Mendeley helps you to discover research relevant for your work.